TAM Receptor
Tyro3; Axl; Mer

TAM receptors (Tyro3, Axl, and Mer) belong to a family of receptor tyrosine kinases that have important effects on hemostasis and inflammation. TAM receptors affect cell proliferation, survival, adhesion, and migration. TAM receptors can be activated by the vitamin K-dependent proteins Gas6 and protein S. Protein S is more commonly known as an important cofactor for protein C as well as a direct inhibitor of multiple coagulation factors.

The TAM receptors-Tyro3, Axl, and Mer-compense a unique family of receptor tyrosine kinases, in that as a group they play no essential role in embryonic development. TAM receptor signaling plays an especially important role in the engulfment and phagocytic clearance of apoptotic cells (ACs) and membranes in adult tissues.
<table>
<thead>
<tr>
<th><strong>TAM Receptor Inhibitors</strong></th>
</tr>
</thead>
</table>

### 2-D08
Cat. No.: HY-114166

2-D08 is a cell permeable, mechanistically unique inhibitor of protein SUMOylation. 2-D08 also inhibits Axl with an IC₅₀ of 0.49 nM.

- **Purity:** 99.04%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Bemcentinib (R428; BGB324)
Cat. No.: HY-15150

Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC₅₀ of 14 nM.

- **Purity:** 99.76%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### BMS 777607 (BMS 817378)
Cat. No.: HY-12076

BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC₅₀ of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all...

- **Purity:** 99.48%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### CEP-40783 (RXDX-106)
Cat. No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC₅₀ values of 7 nM and 12 nM, respectively.

- **Purity:** 99.22%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### BMS 777607
Cat. No.: HY-12076

BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC₅₀ of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all...

- **Purity:** 99.48%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Cabozantinib (XL184; BMS-907351)
Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀ of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

- **Purity:** 99.85%
- **Clinical Data:** Launched
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

### CEP-40783
Cat. No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC₅₀ of 7 nM and 12 nM, respectively.

- **Purity:** 99.22%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Dubermatinib (TP-0903)
Cat. No.: HY-12963

Dubermatinib (TP-0903) is a potent and selective receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.

- **Purity:** 99.53%
- **Clinical Data:** Phase 1
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Gilteritinib (ASP2219)
Cat. No.: HY-12432

Gilteritinib is a potent FLT3/AXL inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

- **Purity:** 99.55%
- **Clinical Data:** Phase 3
- **Size:** 5 mg, 10 mg, 50 mg, 100 mg

### Gilteritinib hemifumarate (ASP2215 hemifumarate)
Cat. No.: HY-12432A

Gilteritinib hemifumarate is a potent FLT3/AXL inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

- **Purity:** 99.75%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg, 50 mg, 100 mg

### Glesatinib hydrochloride (MGCD265 hydrochloride)
Cat. No.: HY-19642A

Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.

- **Purity:** 98.25%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### LDC1267
Cat. No.: HY-12494

LDC1267 is a highly selective TAM (Tyro3, Axl and Mer) kinase inhibitor with IC₅₀ of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively.

- **Purity:** 99.84%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

Tel: 609-228-6898    Fax: 609-228-5909    Email: sales@MedChemExpress.com
**Ningetinib**  
Cat. No.: HY-107145A  
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with $IC_{50}$s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.  
Purity: 98.75%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**Ningetinib Tosylate**  
Cat. No.: HY-107145  
Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with $IC_{50}$s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.  
Purity: 99.88%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**NPS-1034**  
Cat. No.: HY-100509  
NPS-1034 is a dual inhibitor of AXL and MET with $IC_{50}$s of 10.3 and 48 nM, respectively.  
Purity: >98.0%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**R916562**  
Cat. No.: HY-104075  
R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with $IC_{50}$s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 100 mg, 250 mg, 500 mg

**RU-301**  
Cat. No.: HY-119039  
RU-301 is a pan-TAM receptor inhibitor, exerts pan-TAM inhibitory activity by binding at the interface between Gas6 and the Ig1 domain of the respective TAMs with $K_d$ and $IC_{50}$ values of 12 μM and 10 μM, respectively.  
Purity: 99.73%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**SGI-7079**  
Cat. No.: HY-12964  
SGI-7079 is an Axl inhibitor, significantly inhibits the proliferation of SUM149 or KPL-4 cells with an IC50 of 0.43 or 0.16 μM, respectively.  
Purity: 99.65%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**UNC2250**  
Cat. No.: HY-15797  
UNC2250 is a potent and selective Mer inhibitor with an IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.  
Purity: 99.96%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

**UNC2541**  
Cat. No.: HY-125510  
UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50) 510 nM.  
Purity: 98.39%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg
**UNC2881**

Unc2881 is a potent and specific Mer kinase inhibitor; inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM.

- **Purity:** 99.92%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 10 mg, 50 mg

Cat. No.: HY-15798